Jane Street’s Genocea Biosciences, Inc. GNCA Stock Holding History

Jane Street’s Portfolio GNCA Stock Details GNCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-18,433	Closed	-$23K	–	11535
2022 Q1	$23K	Buy	+18,433	New	+$20.1K	﹤0.01%	9905
2020 Q4	–	Sell	-14,508	Closed	-$33K	–	8541
2020 Q3	$33K	Buy	+14,508	New	+$38.1K	﹤0.01%	6980
2019 Q1	–	Sell	-1,808	Closed	-$4K	–	6012
2018 Q4	$4K	Buy	+1,808	New	+$9K	﹤0.01%	4840
2018 Q3	–	Sell	-13,388	Closed	-$92K	–	6041
2018 Q2	$92K	Buy	+13,388	New	+$100K	﹤0.01%	4749

Other funds holding GNCA

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

AICPI

ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return

Jane Street's GNCA Position: Q2 2022 in Review

Jane Street sold out of Genocea Biosciences, Inc. (GNCA) in Q2 2022, closing a stake of 18,433 shares — an estimated $23K sold.

Jane Street first reported a position in GNCA in Q2 2018 and held it in 4 quarters. The position peaked at $92K in Q2 2018. 5 funds tracked by Wall St. Rank hold GNCA as of Q2 2022.

Jane Street reported no remaining Genocea Biosciences, Inc. position as of Q2 2022 after selling out during the quarter.
Jane Street sold 18,433 Genocea Biosciences, Inc. shares in Q2 2022, an estimated $23K.
Jane Street first reported a position in Genocea Biosciences, Inc. in Q2 2018 and held it in 4 quarters.
Jane Street's Genocea Biosciences, Inc. position peaked at $92K in Q2 2018.
5 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q2 2022.

Based on Jane Street's 13F filing for Q2 2022, filed 16 Aug 2022.